Table 1 Incidence of β-catenin-positive lesions at different time points
Genotype | Time point | Number of mice with nuclear β-catenin-positive lesions | |
|---|---|---|---|
Antrum—microadenoma (MA) and adenoma(A) | Corpus—fundic gland polyps (FGP) and adenomatous change (AC) | ||
Experimental mice | |||
AhCreER+ APCfl/fl | Day 4 | MA 8 out of 8 | 0 out of 8 |
Day 6 | MA 3 out of 3 | 0 out of 3 | |
Day 12 | A 3 out of 3 | FGP and AC 3 out of 3 | |
AhCreER+ Catnbexon3fl/exon3fl | Day 4 | MA 4 out of 4 | 0 out of 4 |
Day 11 | A 5 out of 5 | FGP and AC 5 out of 5 | |
AhCreER+ GSK3 | Day 4 | MA 8 out of 8 | 0 out of 8 |
Day 6 | MA 3 out of 9 | FGP 2 out of 9 | |
alphafl/fl betafl/fl | A 6 out of 9 | AC 3 out of 9 | |
Day 8 | A 6 out of 6 | FGP and AC 6 out of 6 | |
Day 12 | A 5 out of 5 | FGP and AC 5 out of 5 | |
Control mice | |||
AhCreER+ | Day 4 | 0 out of 4 | 0 out of 4 |
Day 6 | 0 out of 3 | 0 out of 3 | |
Day 12 | 0 out of 3 | 0 out of 3 | |
AhCreER+ Catnbexon3fl/+ | Day 4 | 0 out of 3 | 0 out of 3 |
Day 6 | 0 out of 5 | 0 out of 5 | |
Day 21 | 0 out of 3 | 0 out of 3 | |
AhCreER+ GSK3 alphafl/fl betafl/+ | Day 6 | 0 out of 3 | 0 out of 3 |
Day 8 | 0 out of 3 | 0 out of 3 | |
Day 12 | 0 out of 5 | 0 out of 5 | |
